Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
US6927221B2 · kind B2 · utility
5Cited by
2References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2004 |
| Grant date | Aug 9, 2005 |
| Priority date | — |
| Expiry date | Aug 2, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof, wherein
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.